Clinical Trial Update: TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

View source ↗

Summary

An update on a long-term safety program for darunavir boosted with ritonavir (TMC114/r) in heavily treatment-experienced HIV-1 patients, with marketing approval…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Norvir (ritonavir)
• PREZISTA (darunavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Status: APPROVED_FOR_MARKETING